Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research
Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has entered into a licensing agreement with The Walter Reed Army Institute of Research (WRAIR) to provide APT access to the Institute’s extensive phage database. The agreement with the United States Army is synergistic with APT’s ongoing partnership with the United States Navy, providing the company with access to the pre-eminent phage database of the United States military to treat critically ill patients.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.